Cellanome
PrivateLast Round
Series B
Jun 22, 2026
Est. Valuation
$525M
Total Funding Raised
$217.75M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cellanome is a biotechnology company that develops an integrated multi-omics platform for high-resolution, large-scale biological measurement and live-cell analysis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Medical Imaging
Business Model
B2B
Customer Profile
Services & Consulting, Hardware + Subscription, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellanome Comparables
Compare Cellanome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mission Bio | 79% | |
| Singleron Biotechnologies | 77% | |
| Neomend | 75% |
Cellanome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 22, 2026 | ||||
| Series B | Jan 29, 2024 | ||||
| Series A | Mar 21, 2023 | ||||
| Seed | Oct 5, 2021 | ||||
| Series A | Jul 1, 2021 |
Cellanome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Angel | Series B, Seed, Series A |
| Khosla Ventures | Series A |
| RONA Holdings | Series A, Seed |
| Wing Venture Capital | Series B, Seed, Series A |
| DFJ Growth | Seed, Series A, Series B |
| Premji Invest | Series B, Seed, Series A |
| 8VC | Series B, Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Raised $76M in Series B funding.
- Apr 1, 2026
Hiring for Director of Product Management for the Cellanome R3200 platform.
Recent news
Latest coverage and updates
- receives_financingJul 17, 2026
Cellanome, Inc. receives financing of $75.9M in funding.
Cellanome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cellanome's valuation, stock price, and market status.
Is Cellanome a public or private company?
Cellanome is a private company.
What is the current stock price of Cellanome?
Cellanome is a private company with no public stock price. No recent secondary market data is available.
How much is Cellanome worth (valuation)?
Cellanome's valuation is estimated at $525.0M based on funding round data.
Can I buy Cellanome stock?
Cellanome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cellanome's last funding round?
Cellanome's most recent funding round was Series B on January 29, 2024.
Who are the main investors in Cellanome?
Key investors in Cellanome include DFJ Growth.
Will Cellanome IPO soon?
No public IPO plans have been announced for Cellanome.
How can I track Cellanome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cellanome's secondary market activity and sign up for updates.